USFDA warns Cipla for lapses in manufacturing practices at Pithampur facility
Written by Arushi Sharma
Cipla, a prominent drug manufacturer, received a warning letter from the USFDA following concerns raised during a routine inspection at its Pithampur facility earlier this year. The letter, dated November 17, 2023.
Drug manufacturer Cipla faced a warning from the United States Food and Drug Administration (USFDA) following an inspection at its Pithampur facility earlier this year.
The routine inspection in February raised concerns regarding the company's adherence to current Good Manufacturing Practices (cGMP).
Cipla confirmed the receipt of the warning letter dated November 17, 2023, outlining specific lapses identified during the inspection.
The letter highlighted deviations from prescribed regulations and provided guidance for necessary corrections.
In response, Cipla pledged to collaborate with the USFDA to rectify the issues flagged at the Pithampur plant.
The company assured a timely and comprehensive approach to address the concerns, emphasizing its commitment to maintaining quality and compliance with cGMP standards.
Cipla's shares closed at Rs 1,234.80 on Friday, November 17, amidst the news of the warning from the USFDA.